Most recently, the soluble urokinase plasminogen activator receptor (suPAR) has been proposed as an alternative and more sensitive biomarker for early identification of those COVID-19 patients at risk of progression who release high amounts of alarmins S100A8/A9 and IL-1α and particularly respond to anakinra, thus allowing the extension of the use of anakinra even to more moderate forms of disease (98). The gene discussed is IL1A; the disease is COVID-19.